Vanderbilt Vaccine Research Program Archive — Page 1 of 3
-
September 7, 2022
VUMC study will evaluate alternative strategies for administering mpox vaccine
Rarely fatal, the mpox virus — spread by close, often skin-to-skin contact — causes a painful, blistering rash, fever, chills and other symptoms. -
July 28, 2022
Study to evaluate nasal flu vaccine for children
Pediatricians with the Vanderbilt Vaccine Research Program are looking for healthy infants and children (6 months – 8 years of age) to take part in a nasal influenza vaccine study. -
May 12, 2022
VUMC-led study finds Moderna COVID vaccine safe and effective for children
-
February 24, 2022
MIS-C diagnosis rare in vaccinated children with no previous COVID-19 diagnosis
A Vanderbilt study found that children who received the COVID-19 vaccine who had not previously been diagnosed with COVID infection are unlikely to be diagnosed with multisystem inflammatory syndrome in children (MIS-C). -
February 3, 2022
Study finds shorter treatment better for young children with outpatient pneumonia
A Vanderbilt study found that five days of antibiotics is superior to 10 days for children with community-acquired pneumonia who are not hospitalized. -
December 8, 2021
Weigh risks, plan ahead prior to gathering for the holidays
Vanderbilt University Medical Center infectious disease experts advise this is the season to think very wisely about planned get-togethers. -
May 12, 2021
Heparin, platelets discouraged as treatment for blood clots after COVID vaccine
Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.